Capstone Investment Advisors
XENE icon

Capstone Investment Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Capstone Investment Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$539K Buy
+8,925
New +$496K ﹤0.01% 1208
2024
Q2 		– Sell
-11,402
Closed -$491K – 2523
2024
Q1 		$491K Buy
11,402
+2,541
+29% +$117K ﹤0.01% 1569
2023
Q4 		$408K Buy
+8,861
New +$313K ﹤0.01% 1439

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Capstone Investment Advisors's XENE Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 8,925 shares worth $539K. The stake represents ﹤0.01% of the portfolio and ranks #1208 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in XENE as recently as Q1 2024.

Capstone Investment Advisors first reported a position in XENE in Q4 2023 and has held it in 3 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Capstone Investment Advisors held 8,925 shares of Xenon Pharmaceuticals worth $539K as of Q2 2026.
  • Xenon Pharmaceuticals was a new Capstone Investment Advisors position in Q2 2026.
  • Xenon Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1208 holding.
  • Capstone Investment Advisors first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 3 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.